Zydus Buys Stake In Sterling Biotech – Will API Segment Restructuring Accelerate?

PE Interest Has Been Growing

Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?

Zydus' Acquisition Of Stake In Sterling Biotech Accelerates Winds Of Change
Zydus' Acquisition Of Stake In Sterling Biotech Accelerates Winds Of Change • Source: Shutterstock

The active pharmaceutical ingredients (API) segment is witnessing a gradual restructuring with an increasing number of large Indian companies expanding their presence via new facilities or stake acquisitions in existing firms.

The latest to join the bandwagon is Zydus Lifesciences Limited, which via subsidiary Zydus Animal Health and Investments Ltd,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business